Metformin vs GLP-1 Agonists: Which Should You Start With?

Written by Aisha Saleem, Pharmacist & Health Writer at PharmaHealths.com

Last Updated: July 10, 2026

What Is Metformin and GLP-1 Agonists?

Metformin and GLP-1 agonists are two different classes of medication used to manage type 2 diabetes, and I get asked constantly which one a person should start on first. With newer diabetes medications gaining attention for weight loss and heart protection, this question has become even more relevant for patients today. Metformin is an oral biguanide that has been the default starting medication for type 2 diabetes for decades. GLP-1 agonists, which include drugs like semaglutide and liraglutide, are injectable or oral medications that mimic a gut hormone involved in blood sugar control and appetite regulation. Both lower blood sugar, but they work through completely different mechanisms and come with different benefits depending on your individual health picture.

How Does Metformin Work?

Metformin lowers blood sugar mainly by reducing how much glucose your liver produces and by improving how your muscles respond to insulin. It does not stimulate the pancreas to release more insulin, which is why it carries very little risk of hypoglycemia on its own. According to NICE, metformin remains the recommended first line medication for most adults with type 2 diabetes, alongside diet and lifestyle changes. It is taken as a tablet, usually starting at a low dose and increasing gradually to reduce stomach upset, and it is inexpensive and widely available as a generic. With long term use, monitoring vitamin B12 levels may be considered, as deficiency can occasionally develop over time.

How Do GLP-1 Agonists Work?

GLP-1 agonists work by mimicking a natural gut hormone that triggers insulin release after meals, slows stomach emptying, and reduces appetite. This is part of why GLP-1 agonists tend to produce noticeably more weight loss than metformin, on top of their blood sugar lowering effect. Most GLP-1 agonists are given as a weekly injection, though an oral version exists for some. They also come with a much higher price tag than metformin and are not always covered by insurance for diabetes alone. In many low- and middle-income settings, cost and access remain major barriers to starting these medications early.

Which One Lowers Blood Sugar More Effectively?

GLP-1 agonists generally produce a stronger reduction in blood sugar and body weight than metformin alone, though metformin remains highly effective as a foundation therapy. Research summarized by the American Diabetes Association shows GLP-1 agonists can produce meaningful weight loss alongside strong glycemic control, with some agents in this class showing the largest blood sugar improvements of any approved diabetes medication.

Metformin’s effect on blood sugar is more modest by comparison, but it has decades of safety data behind it and does not carry the same weight-related cost or access barriers.

Why Do Most Doctors Still Start with Metformin First?

Metformin is usually chosen first because it is affordable, well tolerated long term, and effective for the majority of people newly diagnosed with type 2 diabetes. Current NICE guidance continues to position metformin as the initial treatment for most adults with type 2 diabetes, reserving GLP-1 agonists for specific situations rather than universal first-line use. This is partly a matter of evidence built up over many years, and partly practical, since metformin’s low cost means it is accessible to almost everyone regardless of insurance coverage.

A GLP-1 agonist may be considered earlier than metformin for people with established cardiovascular disease, chronic kidney disease, or a strong need for weight loss alongside blood sugar control. NICE guidance notes that GLP-1 agonists can be offered earlier in the treatment pathway for people with type 2 diabetes and additional cardiovascular or renal risk factors, reflecting their proven protective benefits beyond blood sugar lowering. They may also be considered when higher HbA1c levels require a stronger initial reduction or when obesity is a major contributing factor to disease progression. If metformin is not tolerated or is contraindicated, for example in someone with significantly reduced kidney function, a GLP-1 agonist or another alternative may be used as the first medication instead.

What Are the Side Effects of Each?

Both medications commonly cause digestive side effects, particularly nausea, though the pattern and severity differ between the two. Metformin’s most common complaints are stomach upset and diarrhea, especially when starting or increasing the dose, along with a rare but serious risk of lactic acidosis in people with significant kidney impairment. GLP-1 agonists more commonly cause nausea, vomiting, and slowed digestion, and have been linked in rare cases to pancreatitis and gallbladder problems. They are also generally avoided in individuals with a history of medullary thyroid carcinoma or certain endocrine conditions. Neither medication causes hypoglycemia when used alone, which is an advantage both share over older diabetes drugs like sulfonylureas.

Can Metformin and a GLP-1 Agonist Be Used Together?

Yes, metformin and a GLP-1 agonist are frequently combined, and this is one of the most common treatment pathways in type 2 diabetes care. Rather than being an either-or choice for most patients, metformin often serves as the foundation while a GLP-1 agonist is added if blood sugar targets are not met or if additional cardiovascular, renal, or weight benefits are needed. NICE guidance supports this stepwise approach, adding a GLP-1 agonist to metformin when further glycemic control or additional protective benefit is required, rather than routinely replacing one with the other.

Which One Should You Start With?

For most people newly diagnosed with type 2 diabetes, metformin remains the sensible starting point due to its safety record, affordability, and broad accessibility. If you have established heart disease, kidney disease, or a strong clinical need for weight loss, your prescriber may recommend starting with a GLP-1 agonist instead, or adding one to metformin sooner rather than later. I always tell patients that this decision should weigh their full health picture, including kidney function, cardiovascular risk, weight goals, and what they can realistically access and afford, since the newest medication is not automatically the right first choice for every person.

Conclusion

Metformin remains the first-line choice for most people with type 2 diabetes due to its safety, affordability, and proven effectiveness. GLP-1 agonists offer added benefits like weight loss and cardiovascular protection, making them ideal for selected patients. In practice, the best approach is often a personalized plan, and many people benefit from using both medications together rather than choosing one over the other.

FAQs

Q1. Should I start with metformin or go straight to a GLP-1 medication?
For most people newly diagnosed with type 2 diabetes, metformin is still the recommended starting point due to its safety and affordability. A GLP-1 agonist may be used first if you have established heart or kidney disease, or if metformin is not suitable for you.

Q2. Is metformin still worth taking now that GLP-1 drugs exist?
Yes, metformin remains a foundational treatment and is often combined with a GLP-1 agonist rather than replaced by one. It continues to be recommended as first-line therapy for most adults with type 2 diabetes.

Q3. Can you take metformin and a GLP-1 agonist at the same time?
Yes, this combination is common and often recommended when metformin alone does not achieve blood sugar targets or when additional cardiovascular or renal protection is needed.

Q4. Why did my doctor put me on metformin first instead of a GLP-1?
This usually reflects current clinical guidance, which continues to recommend metformin as the first medication for most people with type 2 diabetes. Cost, accessibility, and decades of safety data all support this approach unless specific risk factors point toward starting differently.

Q5. Does insurance cover GLP-1 agonists as a first medication?
Coverage varies significantly and often depends on whether you have additional risk factors like cardiovascular or kidney disease, since GLP-1 agonists are more likely to be approved as first line treatment in those situations. Metformin is far more likely to be covered without restriction.

Q6. Which one is better if I have prediabetes rather than diabetes?
Metformin is more commonly used for prediabetes, particularly when lifestyle changes alone have not been enough to prevent progression to type 2 diabetes. GLP-1 agonists are generally reserved for confirmed type 2 diabetes or specific weight management indications.

Call to Action

If you are weighing your options for managing type 2 diabetes, you are not alone, and this decision is worth discussing thoroughly with your prescriber. I have written more on diabetes management, blood sugar friendly foods, and other treatment classes over on pharmahealths.com, and I would encourage you to explore those articles as you build your own understanding before your next appointment.

Disclaimer

This article is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always consult your doctor or pharmacist before starting, stopping, or switching any diabetes medication, particularly if you have kidney disease, heart disease, or other underlying health conditions.

References

• National Institute for Health and Care Excellence NICE Type 2 diabetes in adults management NG28 https://www.nice.org.uk/guidance/ng28

• American Diabetes Association Standards of Care in Diabetes https://diabetes.org/health-wellness/standards-of-care